Cholangiocarcinoma Clinical Trials in New York, New York

6 studies are recruiting for cholangiocarcinoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

   This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713.…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   New York University (NYU) Clinical Cancer Center, New York, New York

   Locations

   30 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07213791 on ClinicalTrials.gov

2. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mount Sinai, New York, New York

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

3. Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

   A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   New York Presbyterian Hospital-Columbia University Medical Center, New York, New York

   Locations

   2 in total

   Run by

   Rigel Pharmaceuticals

   See if you can join NCT07486713 on ClinicalTrials.gov

4. A Study of MGC028 in Participants With Advanced Solid Tumors

   The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally ad…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mt. Sinai, New York, New York

   Locations

   7 in total

   Run by

   MacroGenics

   See if you can join NCT06723236 on ClinicalTrials.gov

5. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, New York, New York

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

6. The Dragon PLC Trial (DRAGON-PLC)

   The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary liver cancer compared to standard PVE alone. This trial specific…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   55 in total

   Run by

   Maastricht University

   See if you can join NCT06914648 on ClinicalTrials.gov